Parenteral route of drug administration refers to the administration of drugs through non-oral routes. Large volume parenterals, also termed as large volume injections, are aqueous solutions usually supplied in volumes of at least 100 ml. They include calcium solutions, sodium chloride, ringer's, sodium bicarbonate & other electrolyte solutions, dextrose (glucose) & other sugar solutions, amino acid, peptide & other protein fraction solutions, solutions containing a combination of the above, sometimes with vitamins added, dextrans, and other plasma expanders.
Increase in prevalence of cancer, HIV, and other non-communicable diseases; rapid surge in number of surgeries; and rise in risk of malnutrition drive the growth of the Africa large volume parenterals (LVP) market. However, preference for enteral route of drug administration of therapeutic & nutritional needs and high risk of infection/allergic reaction during a parenteral administration impede the market growth. On the contrary, upsurge in demand for palliative care services in Africa is expected to offer opportunities for market expansion during the forecast period.
The report segments the Africa large volume parenterals market based on treatment type, route of administration, capacity, and country. On the basis of treatment type, the market is classified into fluid balance injections, therapeutic injections, and nutritious injections. Depending on route of administration, it is fragmented into intravenous, intramuscular, subcutaneous, and other routes. LVP are commercially available in 100 ml, 250 ml, 500 ml, 1000 ml, and 2000 ml bottles. Country wise, the market is analyzed across South Africa, Zimbabwe, Namibia, and rest of Africa.
- The study provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent investment pockets.
- It offers a quantitative analysis from 2017 to 2023, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
- Analysis by route of administration helps to understand the various routes for administration of parenteral drugs within the body.
- Comprehensive analysis of major countries within Africa is provided to determine the prevailing opportunities.
- Key players are profiled, and their strategies are analyzed thoroughly to understand the competitive outlook of the market.
By Treatment Type
- Fluid Balance Injections
- Therapeutic Injections
- Nutritious Injections
- 100 ml
- 250 ml
- 500 ml
- 1000 ml
- 2000 ml
- South Africa
- Rest of Africa
- Abacus Parenteral Drugs Limited
- Erongo Med
- Datlabs Private Limited
- Addis Pharmaceuticals Factory PLC
- Pharmacure PLC
- Mascareignes Pharmaceutical Manufacturing Co. Ltd. (operates as a subsidiary of Parenteral Drug (India) Ltd.)
- Adcock Ingram Holdings Ltd.
1.1. Report description
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. KEY FINDINGS OF THE STUDY
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. Key Findings
3.2.1. Top investment pockets
3.2.2. Top player positioning, 2016
3.3. MARKET DYNAMICS
220.127.116.11. Increase in number of surgical procedures
18.104.22.168. Rise in prevalence of chronic diseases
22.214.171.124. Rise in risk of malnutrition
126.96.36.199. Risk of allergic reaction and infection
188.8.131.52. Preference for enteral route of administration
184.108.40.206. Upsurge in demand for palliative care
CHAPTER 4: AFRICA LARGE VOLUME PARENTERALS MARKET, BY TREATMENT TYPE
4.1.1. Market size and forecast
4.2. Fluid balance injections
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast
4.3. Therapeutic Injections
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast
4.4. Nutritious injections
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast
CHAPTER 5: AFRICA LARGE VOLUME PARENTERALS MARKET, BY ROUTE OF ADMINISTRATION
5.1.1. Market size and forecast
5.2.1. Market size and forecast
5.3.1. Market size and forecast
5.4.1. Market size and forecast
5.5. Other routes
5.5.1. Market size and forecast
CHAPTER 6: AFRICA LARGE VOLUME PARENTERALS MARKET, BY CAPACITY
6.1.1. Market size and forecast
6.2. 100 ml
6.2.1. Market size and forecast
6.3. 250 ml
6.3.1. Market size and forecast
6.4. 500 ml
6.4.1. Market size and forecast
6.5. 1000 ml
6.5.1. Market size and forecast
6.6. 2000 ml
6.6.1. Market size and forecast
CHAPTER 7: AFRICA LARGE VOLUME PARENTERALS MARKET, BY COUNTRY
7.1.1. Market size and forecast
7.2. South Africa
7.2.1. Market size and forecast
7.3.1. Market size and forecast
7.4.1. Market size and forecast
7.5. Rest of Africa
7.5.1. Market size and forecast
CHAPTER 8: COMPANY PROFILE
8.1. Parenteral Drugs (India) Ltd.
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.2. Adcock Ingram Holdings Ltd.
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.3. Pharmacure PLC
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Product portfolio
8.4. Datlabs Private Limited
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.5. Erongo Med
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.6. Addis Pharmaceutical Factory PLC.
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Key strategic moves and developments
8.7. Abacus Parenteral Drugs Limited
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Product portfolio
Parenteral route of drug administration refers to administration of drugs through non-oral routes. Large volume parenterals, also termed as large volume injections, are aqueous solutions usually supplied in volumes of at least 100 ml. They include calcium solutions, sodium chloride, ringer's, sodium bicarbonate and other electrolyte solutions, dextrose (glucose) & other sugar solutions, amino acid, peptide & other protein fraction solutions, solutions containing a combination of the above, sometimes with vitamins added, dextrans, and other plasma expanders.
Increase in prevalence of chronic diseases, rapid surge in number of surgeries, and rise in risk of malnutrition are the major factors that drive the growth of the Africa large volume parenterals (LVP) market. However, preference for enteral nutrition and high risk of infection/allergic reaction during a parenteral administration restrain the market growth. Conversely, increase in demand for palliative care services in Africa is expected to offer potential growth opportunities for the market in the near future.
On the basis of treatment type, fluid balance injections segment dominated the market in 2017 by garnering nearly two-thirds share, and is expected to maintain its dominance during the analysis period. This is attributed to the fact that fluid balance injections can be used for a broad customer base, including patients who are critically ill, septic, with major cardiac, liver or renal comorbidity, or after a major surgery.
Based on route of administration, the intravenous segment held the major market share of more than four-fifths in 2017, and is expected to dominate the market throughout the analysis period, since it is the fastest way to deliver large volume parenterals, as the drug is easily carried throughout the body with the help of circulation.
Key findings of the Africa Large Volume Parenterals Market:
Intramuscular segment is expected to grow with a CAGR of 8.2% from 2018 to 2024.
By treatment type, the nutritious injections segment is expected to grow at the highest CAGR of 9.1% from 2018 to 2024.
The 500 ml capacity segment held a major share of more than four-fifths and three-fourths in terms of value and volume, respectively, in 2017, and is expected to maintain this trend throughout the analysis period.
South Africa held a major share of more than one-fifth in the African market in 2017, and is expected to retain it throughout the analysis period.
Namibia is expected to register a CAGR of 7.7% from 2018 to 2024.
Based on country, South Africa is expected to dominate the Africa LVP market during the analysis period. Furthermore, Namibia is expected to grow at the highest CAGR and offer lucrative opportunities to market players in the coming future.
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.